Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS   US4643301090

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

ISIS Pharmaceuticals, Inc. : Webcast Alert: Isis Pharmaceuticals' First Quarter 2013 Financial Results Conference Call

05/02/2013 | 01:00pm US/Eastern
Recommend:
0

CARLSBAD, Calif., May 2, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:

    What:   Isis Pharmaceuticals' First Quarter 2013
            Financial Results and Highlights Conference
            Call

    When:   Tuesday, May 7, 2013 at 4:30 p.m. ET /1:30
            p.m. PT

    Where: www.isispharm.com

    How:    Live on the Internet.  Simply log onto our Web
            site listed above.

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO(TM), in the United States for the treatment of patients with HoFH. Genzyme is also pursuing marketing approval of KYNAMRO in other markets. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT

This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012, which is on file with the SEC. Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc. Regulus Therapeutics(TM) is a trademark of Regulus Therapeutics Inc. KYNAMRO(TM) is a trademark of Genzyme Corporation.

SOURCE Isis Pharmaceuticals Inc.

Recommend :
0
React to this article
Latest news on ISIS PHARMACEUTICALS, INC.
1d ago ISIS PHARMACEUTICALS : Initiates Phase 2 Study of ISIS-APOa Rx in Patients with ..
7d ago ISIS PHARMACEUTICALS : Initiates Phase 2 Study of ISIS-APO(a) Rx in Patients wit..
07/16 ISIS PHARMACEUTICALS : Earns $1 Million from GSK for Advancing ISIS-TTR Rx
07/15 ISIS PHARMACEUTICALS : Excaliard Pharmaceuticals Assigned Patent
07/09 ISIS PHARMACEUTICALS : New Cancer Gene Therapy Study Findings Reported from Isis..
07/08 ISIS PHARMACEUTICALS : Assigned Patent
07/02 GLAXOSMITHKLINE : Isis Pharma Earns USD1 Million From Glaxo For Advancing Hepati..
07/02 ISIS PHARMACEUTICALS : Earns $1 Million From GSK for Advancing Hepatitis B Virus..
07/02 ISIS PHARMACEUTICALS : to Speak at Pharmica Consulting's West Coast SharePoint C..
06/26 ISIS PHARMACEUTICALS : Earns $10 Million Milestone Payment from Biogen Idec
Dynamic quotes  
ON
| OFF